CareDx Inc. (CDNA)
NASDAQ: CDNAHealthcareDiagnostics & ResearchUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 63.04 0.00%
CDNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.26B
- P/E (TTM)
- 30.31
- Forward P/E
- 48.87
- EPS (TTM)
- $2.08
- Dividend yield
- None
- 52-week range
- 13.95 – 72.51
- Day range
- 61.38 – 65.10
- Volume / Avg
- 1.70M / 1.28M
- Beta
- —
- Shares outstanding
- 51.73M
- Next earnings
- Nov 3, 2026
52-week range
CDNA stock today
Shares of CareDx (CDNA) finished lower on Oct 7 at $63.04, a drop of 1.18% or $0.75 per share, versus the S&P 500's 0.22% decline. At this level, CDNA sits near the top of its 52-week range of $13.95 to $72.51: 13.1% below the high, set on Oct 6, 2026 and 351.9% above the low. CDNA is up 236.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 331.6%.
At 30.3x trailing earnings, CareDx trades in line with the peer-group median of 31.4x. Its forward P/E of 48.9x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. CareDx's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About CareDx
Company profileCareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- CEO
- Mr. John Walter Hanna Jr.
- Headquarters
- Brisbane, CA
- Employees
- 761
- IPO year
- 2014
- Website
- caredx.com
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$58.83-6.68%
- Strong buy 0
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.07
CDNA news
All CDNA newsCareDx peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VCYTVeracyte Inc. | 43.16 | -3.34% | $3.47B | vs CDNA |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs CDNA |
| BLLNBillionToOne Inc. Class A | 95.75 | -4.19% | $4.52B | vs CDNA |
| NEONeoGenomics Inc. | 15.97 | -3.24% | $2.05B | vs CDNA |
| WGSGeneDx Holdings Corp. Class A | 68.53 | -4.18% | $2.04B | vs CDNA |
| FRNMFreenome Inc. | 16.03 | -2.02% | $1.72B | vs CDNA |
| PSNLPersonalis Inc. | 16.00 | -0.19% | $1.71B | vs CDNA |
| SHCSotera Health Company | 17.90 | -1.92% | $5.11B | vs CDNA |
Indexes, lists and sector
Appears in lists
CareDx stock FAQ
What is CareDx's stock price today?
CDNA last traded at $63.04 as of Oct 7, 4:00 PM EDT, down 1.18% on the day. Prices are delayed at least 15 minutes.
When is CareDx's next earnings date?
CareDx is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.07.
What is CDNA's P/E ratio?
CDNA trades at a trailing P/E ratio of 30.31 and a forward P/E of 48.87, compared with a median of 31.4 for its closest peers.
Who is CareDx's CEO?
Mr. John Walter Hanna Jr. is the chief executive officer of CareDx Inc., which has about 761 employees.
What is the CDNA 52-week high?
The 52-week high for CDNA is $72.51 and the 52-week low is $13.95. The stock is currently 13.1% below its high.